drugset / Trial / NCT05817890

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

NCT05817890

Phase 0 Completed 8 enrolled Cyclacel Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This will be a Phase 1, open-label, single dose study of the Absorption, Metabolism, and Excretion of CYC065 in healthy male subjects.

Timeline

Start
2023-03-03
Primary completion
2024-02-29
Completion
2024-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CYC065 Small molecule Oral

Indications

No indication recorded.